ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MCRB Seres Therapeutics Inc

0.7521
0.0226 (3.10%)
Last Updated: 11:37:48
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,099,751
Bid Price 0.7503
Ask Price 0.754
News -
Day High 0.829

Low
0.54

52 Week Range

High
6.7299

Day Low 0.700201
Company Name Stock Ticker Symbol Market Type
Seres Therapeutics Inc MCRB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0226 3.10% 0.7521 11:37:48
Open Price Low Price High Price Close Price Prev Close
0.7132 0.700201 0.829 0.7295
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,218 2,099,751 $ 0.7717911 $ 1,620,569 - 0.54 - 6.7299
Last Trade Time Type Quantity Stock Price Currency
11:37:27 100 $ 0.7521 USD

Seres Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
113.26M 151.01M - 126.33M -113.72M -0.75 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Seres Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MCRB Message Board. Create One! See More Posts on MCRB Message Board See More Message Board Posts

Historical MCRB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.62730.8290.540.68650115,884,2580.124819.89%
1 Month0.7870.8290.540.69627364,607,071-0.0349-4.43%
3 Months1.151.240.540.8751364,121,265-0.3979-34.60%
6 Months1.552.050.541.074,657,761-0.7979-51.48%
1 Year6.466.72990.542.283,785,096-5.71-88.36%
3 Years20.6525.0550.544.482,093,059-19.90-96.36%
5 Years6.8438.500.547.441,587,702-6.09-89.00%

Seres Therapeutics Description

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Your Recent History

Delayed Upgrade Clock